Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $679.29M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.29M
Average 0.45M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$14.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Oruka Therapeutics, Inc. NASDAQ:ORKA | $7.15B | $105.35 | Not rated | -33.9 | +250.89% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +84.88% |
MoonLake Immunotherapeutics NASDAQ:MLTX | $1.06B | $12.50 | Not rated | -5.4 | -16.04% |
Alumis Inc. Common Stock NASDAQ:ALMS | $724.84M | $5.60 | Not rated | -12.2 | -24.49% |
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $621.76M | $3.92 | Not rated | -8.2 | +35.74% |
AgomAb Therapeutics N.V. American Depositary Shares NASDAQ:AGMB | $313.22M | $6.36 | Not rated | -7.1 | — |
Evommune, Inc. NYSE:EVMN | $276.91M | $7.63 | Not rated | -9.1 | -65.23% |
Q32 Bio Inc. NASDAQ:QTTB | $260.64M | $8.71 | Not rated | 5.4 | +278.51% |
Zura Bio Limited NASDAQ:ZURA | $119.44M | $1.24 | Not rated | -5.5 | -72.98% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $42.65M | $0.68 | Not rated | -4.0 | -68.79% |
Continue the stock analysis
Jump to another research area for this company.